We are very happy to share our latest review paper! The power of personalized immunotherapy is becoming more and more apparent. The data presented at the AACR Annual meeting and the Neoantigen Summit this spring is exciting and showcases the momentum...
Recently we enjoyed some delicious and freshly shaken, but not stirred, (m)(c)ocktails with the myNEO team. It was great catching up with everyone. #workhardplayhardThanks Deloitte for this great reward! #fast50 Enjoy the pictures !
myNEO Therapeutics launches myNEO Tx academy on LinkedIn as we believe in the power of education! Each month we will touch upon a different topic to inform you and get you as excited as we are about neoantigen discovery and cancer immunotherapy! Follow-us on LinkedIn...
myNEO Therapeutics’ CEO, Cedric Bogaert, recently won a spot on the Forbes30under30 List 2023! We are very honored and excited about this achievement. Here is what he had to say about earning the spot. “What started out 6 years ago as experimenting with some...
Odimma Therapeutics and myNEO Therapeutics will partner to identify personalized targets for clinical development of DNA-based cancer vaccine therapy. The myNEO Therapeutics project team is excited to have Odimma as our newest partner, and to be able to enter the...
